文献速递脑血管病认知障碍与痴呆

口服抗凝药与非瓣膜性心房颤动患者痴呆风险:一项基于人群的队列研究

Oral Anticoagulants and the Risk of Dementia in Patients With Nonvalvular Atrial Fibrillation: A Population-Based Cohort Study.
PubMed 文献 · Neurology · 2022-12-29

该研究基于英国临床实践研究数据链,纳入142227例新诊断非瓣膜性心房颤动患者,评估口服抗凝药使用与痴呆风险的关系。结果显示,与未使用相比,口服抗凝药使用与痴呆风险降低相关(HR 0.88,95%CI 0.84-0.92),且风险降低在75岁及以上患者中更明显(HR 0.84,95%CI 0.80-0.89),而在年轻患者中无显著关联(HR 0.99,95%CI 0.90-1.10)。

要点

  • 口服抗凝药使用与痴呆风险降低相关(HR 0.88,95%CI 0.84-0.92)。
  • 75岁及以上患者中风险降低更明显(HR 0.84,95%CI 0.80-0.89)。
  • 年轻患者中未见显著关联(HR 0.99,95%CI 0.90-1.10)。

核心结论

  • 在新诊断非瓣膜性心房颤动患者中,口服抗凝药使用与痴呆风险降低相关,尤其在老年患者中。

研究设计与样本

  • 基于英国临床实践研究数据链的基于人群的队列研究,纳入1988年至2017年间新诊断非瓣膜性心房颤动且既往未使用口服抗凝药的50岁及以上患者,随访至2019年。
  • 共纳入142227例患者,随访662667人年,发生8023例痴呆。
  • 采用时间依赖Cox回归模型估计风险比(HR),调整54个协变量,并评估累积使用时长的影响。

主要发现

  • 口服抗凝药使用与痴呆风险降低相关(HR 0.88,95%CI 0.84-0.92), compared with nonuse。
  • 限制性立方样条显示,累积使用约1.5年时风险降至最低,此后趋于稳定。
  • 75岁及以上患者中风险降低(HR 0.84,95%CI 0.80-0.89),年轻患者中无显著关联(HR 0.99,95%CI 0.90-1.10)。

关键数值与推荐

  • 痴呆发病率12.1/1000人年(95%CI 11.9-12.4)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Nonvalvular atrial fibrillation (NVAF) is associated with an increased risk of dementia. Oral anticoagulants (OACs) are essential for stroke prevention in NVAF, and studies have shown a possible protective effect on dementia. However, findings have been inconsistent and hampered by methodological limitations. Thus, we assessed whether the use of OACs is associated with a decreased incidence of dementia in patients with NVAF. In addition, we explored the impact of the cumulative duration of OAC use on the incidence of dementia. METHODS: Using the UK Clinical Practice Research Datalink, we formed a cohort of all patients aged 50 years or older with an incident diagnosis of NVAF between 1988 and 2017 and no prior OAC use, with a follow-up until 2019. Patients were considered unexposed until 6 months after their first OAC prescription for latency considerations and exposed thereafter until the end of follow-up. We used time-dependent Cox regression models to estimate hazard ratios (HRs), adjusted for 54 covariates, with 95% CIs for dementia associated with OAC use, compared with nonuse. We also assessed whether the risk varied with the cumulative duration of OAC use, compared with nonuse, by comparing prespecified exposure categories defined in a time-varying manner and by modeling the HR using a restricted cubic spline. RESULTS: The cohort included 142,227 patients with NVAF, with 8,023 cases of dementia over 662,667 person-years of follow-up (incidence rate 12.1, 95% CI 11.9-12.4 per 1,000 person-years). OAC use was associated with a decreased risk of dementia (HR 0.88, 95% CI 0.84-0.92) compared with nonuse. A restricted cubic spline also indicated a decreased risk of dementia, reaching a low at approximately 1.5 years of cumulative OAC use and stabilizing thereafter. Moreover, OAC use decreased the risk in patients aged 75 years and older (HR 0.84, 95% CI 0.80-0.89), but not in younger patients (HR 0.99, 95% CI 0.90-1.10). DISCUSSION: In patients with incident NVAF, OACs were associated with a decreased risk of dementia, particularly in elderly individuals. This warrants consideration when weighing the risks and benefits of anticoagulation in this population. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with NVAF, OAC use (vs nonuse) is associated with a decreased risk of dementia.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Rahman AA, Michaud J, Dell'Aniello S, et al. Oral Anticoagulants and the Risk of Dementia in Patients With Nonvalvular Atrial Fibrillation: A Population-Based Cohort Study. Neurology. 2022. PMID: 36581462. doi:10.1212/WNL.0000000000206748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。